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▼The two-primer method of site-directed mutagenesis de-
scribed by Deng and Nickoloff (Ref. 1), allows the rapid
introduction of base changes to inserts in many commonly
used plasmids. One primer carries the desired mutation,
whilst a second selection primer destroys a unique non-
essential restriction enzyme site, hence Unique Site Elim-
ination (USE) mutagenesis. USE mutagenesis kits and a
range of selection primers are available from two suppli-
ers [TransformerTM site-directed mutagenesis kit (Clontech)
and USE mutagenesis kit (Pharmacia)]. Following anneal-
ing and polymerization steps, the plasmid is digested with
the enzyme which recognizes the site eliminated by the
selection primer, and then transformed en masse into a
mutS mismatch-repair deficient Escherichia coli strain. As
circular DNA is transformed into bacteria 10- to 1000-fold
more efficiently than linear DNA (Ref. 2), mutated plas-
mid is preferentially propagated. DNA recovered from this
transformation will be a mixture of mutated and parent
plasmid. This DNA is again digested with the same en-
zyme, transformed into bacteria and plated out to give
single colonies for screening. Variability in mutagenesis
efficiency depends upon a number of factors such as the
quality of the template and primers, the plasmid being
used and the primer sequence itself. For example, it has
been reported that the pBluescript (Stratagene) vectors give
better results if the polymerization step is carried out at
higher temperatures (Ref. 3 and Pharmacia USE Instruction
Booklet).
Here we describe a simple modification that we have
found improves the efficiency of mutagenesis with our
plasmid, pSVL (Pharmacia), a eukaryotic expression vec-
tor. Mutagenesis was performed with the USE mutagenesis
kit (Pharmacia)and ScaI/MluI USE selection primer (Phar-
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Table 1. Effect of changing primer ratio on the
efficiency of mutagenesis Ratio of mutagenic
primer to selection primer Mutation efficiency
Sca I site elimination
1:1 2/12 (16.6%) 12/12
10:1 9/12 (75%) 12/12
macia). This primer anneals to the ampicillin resistance
gene of pSVL without affecting its function, and converts
the unique ScaI site into an MluI site. A second ‘toggle’
primer is also supplied which converts this MluI site into
a ScaI site, allowing multiple rounds of mutagenesis with-
out subcloning. We have observed a moderate improve-
ment in the efficiency of mutagenesis if the polymeriza-
tion step is carried out at 42◦C, as has been reported for
other plasmids (Pharmacia USE Instruction Booklet). In
this experiment, we created a DraIII site using a 28-mer
oligonucleotide primer which introduced two base changes
to our template. Here we show that simply increasing the
ratio of mutagenic primer to selection primer can signif-
icantly improve the efficiency of mutagenesis by several
fold (Table 1). As there is no selection for the mutagenic
primer, we have increased the amount added from 1:1 to
10:1 with respect to the selection primer. All the colonies
screened had lost the ScaI site which implies that the se-
lection primer has destroyed this enzyme recognition se-
quence. This modification in primer ratio was effective for
a number of mutagenic primers used with this template
(pSVL).
In summary, whilst some plasmids may benefit from
higher polymerization reaction temperatures, others may
give better results using this modification. Thus, by sim-
ply biasing the ratio of primers in favour of the desired
mutation, a significant improvement in efficiency can be
achieved.
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Products Used
Transformer: Transformer from Clontech Inc
Transformer: Transformer from Clontech Inc
USE mutagenesis kit: USE mutagenesis kit from
Pharmacia
pBluescript: pBluescript from Stratagene
USE mutagenesis kit: USE mutagenesis kit from
Pharmacia
USE selection primer: USE selection primer from
Pharmacia
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